Program
atogepant
Also written as “Atogepant”, “Atogepant 60 mg” and “Atogepant 30 mg”.
Its studies are mostly in Migraine Disorders, led by AbbVie.
Drug pageAtogepant: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 194 open or running | phase 4since Feb 22, 2022 | Jul 26, 2016 | Mar 2028phase 3 · NCT05711394 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 3 earlier studies, Jul 26, 2016 to Dec 13, 2018.
- Dec 9, 2016Named atogepantINNProposed as its International Nonproprietary Name in WHO's List 116
- Feb 25, 2019Phase 3 study in Chronic MigraineNCT03855137 · 778 enrolled · United States, Australia, Canada and more
- May 3, 2019Phase 3 study in Migraine DisordersNCT03939312 · 685 enrolled · United States
- Jun 16, 2020Phase 3 study in Chronic MigraineNCT04437433 · 186 enrolled · Japan
- Dec 21, 2020Phase 3 study in Episodic MigraineNCT04686136 · 596 enrolled · United States, Canada, Czechia and more
- Feb 2, 2021Phase 3 study in Episodic MigraineNCT04740827 · 315 enrolled · United States, Australia, Canada and more
- Mar 24, 2021Phase 1 study in Migraine DisordersNCT04818515 · 26 enrolled · United States
- Apr 1, 2021Phase 3 study in Migraine DisordersNCT04829747 · 3 enrolled · China
- Jan 19, 2022Phase 3 study in Migraine DisordersNCT05216263 · 75 enrolled · United States
- Feb 22, 2022Phase 4 study in Episodic MigraineNCT05264129 · 263 enrolled · United States
- Jan 24, 20232 phase 3 studiesNCT05707949, NCT05711394
- May 8, 2023Phase 3 study in Migraine DisordersNCT05861427 · 524 enrolled · Japan
- May 30, 2023Phase 1 study in Healthy VolunteersNCT05892757 · 24 enrolled · United States
- Jan 28, 2024Phase 3 study in Migraine DisordersNCT06241313 · 2,158 enrolled · Belgium, China, Czechia and more
- Jan 29, 20252 phase 3 studiesNCT06806293, NCT06810505
Ahead
- Mar 2028Primary completion: phase 3 study in Episodic MigraineNCT05711394
- Mar 2031Primary completion: phase 3 study in Migraine DisordersNCT06810505
- Apr 2032Primary completion: phase 3 study in Migraine ProphylaxisNCT05707949
TargetBeta
“An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the preventive treatment of migraines”NCIt, by rule
“Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ubrogepantrule | AbbVie | phase 4 | 13 |
| zavegepantrule | Pfizer | phase 3 | 13 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06810505Migraine Disorders · United States, Canada, Denmark and more | 3 | Recruiting | Mar 2031 | 420 |
| NCT06806293Menstrual Migraine (MM) · China, Czechia, Germany and more | 3 | Active, not recruiting | Jun 29, 2026 | 468 |
| NCT06241313Migraine Disorders · Belgium, China, Czechia and more | 3 | Completed | Jul 7, 2025 | 2,158 |
| NCT05892757Healthy Volunteers · United States | 1 | Completed | Feb 22, 2024 | 24 |
| NCT05861427Migraine Disorders · Japan | 3 | Completed | Mar 1, 2025 | 524 |
| NCT05711394Episodic Migraine · United States, Belgium, Canada and more | 3 | Recruiting | Mar 2028 | 450 |
| NCT05707949Migraine Prophylaxis · United States, Belgium, Canada and more | 3 | By invitation | Apr 2032 | 650 |
| NCT05264129Episodic Migraine · United States | 4 | Completed | Apr 4, 2023 | 263 |
| NCT05216263Migraine Disorders · United States | 3 | Completed | May 2, 2025 | 75 |
| NCT04829747Migraine Disorders · China | 3 | Completed | Jan 20, 2022 | 3 |
| NCT04818515Migraine Disorders · United States | 1 | Completed | Jun 18, 2021 | 26 |
| NCT04740827Episodic Migraine · United States, Australia, Canada and more | 3 | Completed | Aug 4, 2022 | 315 |
| NCT04686136Episodic Migraine · United States, Canada, Czechia and more | 3 | Completed | Oct 20, 2025 | 596 |
| NCT04437433Chronic Migraine · Japan | 3 | Completed | Jun 11, 2024 | 186 |
| NCT03939312Migraine Disorders · United States | 3 | Completed | Mar 31, 2021 | 685 |
| NCT03855137Chronic Migraine · United States, Australia, Canada and more | 3 | Completed | Jan 20, 2022 | 778 |
| NCT03777059Migraine Disorders · United States | 3 | Completed | Jun 19, 2020 | 910 |
| NCT03700320Episodic Migraine · United States | 3 | Completed | May 21, 2020 | 744 |
| NCT02848326Migraine Disorders · United States | 3 | Completed | Apr 2, 2018 | 834 |
How it is read
Names in the registry
- “Atogepant”, 15 entries
- “Atogepant 60 mg”, 4 entries
- “Atogepant 30 mg”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.